Key facts
- It has raised $16.7M; the latest was Early Stage VC ($13.9M) in Aug 2025.
- Notable investors include HSG (Hong Kong), YuanBio Venture Capital, Sinovation Ventures, Heda Ventures, Chengxin VC — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Ribopeutic
- ·The full record, as it builds
Funding rounds
No funding rounds for Ribopeutic are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ribopeutic
Developer of AI-powered small molecule drugs designed for targeting RNA in the treatment of cancer, rare diseases, and viral infections. The company focuses on discovering novel RNA targets suitable for drug development using an internationally leading AI-driven, wet-dry closed-loop RNA target discovery platform, providing clients with innovative drugs aimed at addressing unmet clinical needs in these areas.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2022
- Website
- ribopeutic.com/
- Ownership
- Privately Held (backing)
Ribopeutic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ribopeutic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ribopeutic in its N-PORT filings yet. We sweep new filings monthly.